Connect with us


Carroucell raises €1.5 million in gene therapy financing



Carroucell, the microcarrier supplier for bioreactor cell culture, has raised €1.5 million.

The funding includes the closing of a Series A financing, led by the Novalis Biotech Acceleration fund with support from Crédit Agricole des Savoie (CADS) and Bpifrance.

The funding will help accelerate corporate growth through industrialisation of the company’s platform technology and ramping up of mass production processes to GMP standards.

Carroucell has developed a platform that offers flat-shape microcarriers with a glass xenofree composition for cell culture in bioreactors.

This combination of novel microcarriers combined with the flexibility of the production process enables a faster, more optimised scale-up of the clinical phases, the company said.

This more cost-effective process could provide customers with a faster pathway to market.

Tarek Fathallah, Founder and President of Carroucell, said:

“For the first time, microcarrier customization and a more customer-oriented service are available for the development of the new applications into the cell culture and bioproduction market.

“There are many challenges with biomanufacturing performance.

“We believe our unique microcarrier technology and ability to address customer specific needs will overcome most challenges and stimulate a revolution in the sector moving forward.”

Jan Van den Berghe, co-founder and managing director of Novalis Biotech, who has also been appointed to the board of directors, added:

“Carroucell is creating a new standard in biomanufacturing, which could help to facilitate patient access to many more innovations in cell and gene therapy in the future.

“When customers adopt Carroucell’s technology platform, they are able to optimise the yield and the quality of the cell culture, solving the low-performance problem in bioproduction we see today.”

Takis Breyiannis, CEO of Carroucell, said:

“The complex environment of cell culture in bioreactors and the increasing number of new applications requires an innovative approach to guarantee the balance of the system.

“Carroucell’s microcarrier plays the role of regulator of this system by ensuring its optimisation.”

Continue Reading


  1. Pingback: Around the Health Tech World: Dr. Anna van Poucke

  2. Pingback: Aspect Biosystems appoints trio to board | Health Tech World

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories